Table 6 Crude incidence rates of serious skin disorders among current users of oral antifungals
From: Risk of serious skin disorders among users of oral antifungals: a population-based study
Antifungal | Patients | Person-years | Cases | Cumulative incidence per 10,000 patients | Incidence rate per 10,000 person-years | Relative risk* (95% CI) |
|---|---|---|---|---|---|---|
Fluconazole | 26,992 | 1,927 | 2 | 0.7 (0.01–2.7) | 10.4 (1.3–37.5) | 2.6 (0.3–10.1) |
Griseofulvin | 4,941 | 2,158 | 1 | 2.0 (0.1–11.3) | 4.6 (0.1–25.8) | 1.2 (0.03–6.9) |
Itraconazole | 15,329 | 1,296 | 2 | 1.3 (0.2–4.7) | 15.4 (1.9–55.7) | 3.9 (0.5–15.0) |
Ketoconazole | 737 | 89 | 0 | 0.0 (0.0–50.1) | 0.0 (0.0–414.3) | 0.0 (0.0–109.9) |
Terbinafine | 13,859 | 3,596 | 4 | 2.9 (0.8–7.4) | 11.1 (3.0–28.5) | 2.8 (0.7–7.8) |